This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
On Jun 4, we issued an updated research report on NuVasive, Inc. (NUVA - Free Report) . We are upbeat about the company’s flourishing international business, which holds immense opportunity. However, a highly competitive landscape is a concern for this Zacks Rank #3 (Hold) company.
BRK.A DB SYK NUVA ISRG ZBH
Medtronic (MDT) is the largest pure-play medical device company in the world. It offers products across four segments: CVG (Cardiac and Vascular Group), MITG (Minimally Invasive Therapies Group), RTG (Restorative Therapies Group), and DG (Diabetes Group). Since the company’s earnings release on May 24, MDT stock has fallen ~1.8%. Let’s see what Wall Street analysts are recommending for the stock.
ABT MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS ZBH MS.PRA ABT
Align Technology (ALGN) hosted its 2018 Investor Day on May 23. On the day, the company provided an updated long-term revenue growth target range and reaffirmed its Q2 2018 and 2018 guidances. It also discussed its key growth drivers, its digital platform, and its recently announced products, and it presented its Invisalign palatal expander for the first time.
ALGN XRAY ZBH HSIC
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) recently announced the receipt of 510(k) clearance from the FDA for its Zyston Strut Open Titanium Interbody Spacer System, which is expected to revitalize the Spine division. Notably, the product is the company’s first titanium spinal implant to be built using the 3D printing technology.
TAPOF ROP TPOYY AMED ISRG ZBH ILMN TAP
Chicago, IL – May 23, 2018 – Zacks Equity Research highlights Generac (GNRC - Free Report) as the Bull of the Day and Maximus (MMS - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Norbord (OSB - Free Report) , Boeing (BA - Free Report) and Zimmer Biomet Holdings (ZBH - Free Report) .
MMS STT TPOYY KBH DB STT.PRC STT.PRE STT.PRD STT.PRG ZBH OSB TAPOF X GNRC KHC TAP
On Sunday, the U.S. and China put trade tensions aside in hopes of reaching a stable and broad trade agreement. With previously at-risk stocks beginning to rise, there seems to be room for profit in these formerly questionable markets. Read on for three stocks that investors should reconsider as the trade war is put on hold.
TAPOF TPOYY KHC ZBH TAP OSB
zbh-8k_20180515.htm UNITED STATES
zbh-10q_20180331.htm UNITED STATES
Dentsply Sirona (XRAY) is one of the leading dental technology providers in the United States. The company will announce its 1Q18 earnings results on May 7. It’s currently undergoing a restructuring program after failing to realize the expected synergies from its Dentsply International and Sirona Dental Systems merger in February 2016.
ALGN XRAY SIRO ZBH
To say that hedge fund and mutual fund managers tend to follow the herd is an incredible understatement and always has been. While publicly they sometimes seem reluctant to discuss their holdings, especially stocks they short, the reality is managers tend to talk among themselves as they run in the same circles. Often those discussions are centered around their portfolios and what is in them.
Zimmer Biomet Holdings (ZBH) announced its 1Q18 earnings results today. The company reported net sales of $2.018 billion, registering YoY (year-over-year) growth of ~2.3%. However, on a constant-currency basis, the company reported a YoY sales decline of ~1.5%. For fiscal 1Q18, Zimmer Biomet Holdings reported adjusted EPS (earnings per share) of $1.91, down ~10.3% on a YoY basis. Reported sales, as well as EPS results, however, exceeded analysts’ estimates in the quarter.
1h - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
2018-07-09 - Asif
Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...
as of ET